Logo image of CGTX

COGNITION THERAPEUTICS INC (CGTX) Stock Price, Quote, News and Overview

NASDAQ:CGTX - Nasdaq - US19243B1026 - Common Stock - Currency: USD

0.7054  +0.04 (+5.69%)

CGTX Quote, Performance and Key Statistics

COGNITION THERAPEUTICS INC

NASDAQ:CGTX (8/4/2025, 2:48:06 PM)

0.7054

+0.04 (+5.69%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.29
52 Week Low0.22
Market Cap43.73M
Shares61.99M
Float61.49M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO10-08 2021-10-08


CGTX short term performance overview.The bars show the price performance of CGTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 60

CGTX long term performance overview.The bars show the price performance of CGTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CGTX is 0.7054 USD. In the past month the price increased by 64.79%. In the past year, price decreased by -8.4%.

COGNITION THERAPEUTICS INC / CGTX Daily stock chart

CGTX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 55.77 727.23B
JNJ JOHNSON & JOHNSON 17 409.49B
AZN ASTRAZENECA PLC-SPONS ADR 16.74 230.46B
NVS NOVARTIS AG-SPONSORED ADR 13.28 227.60B
NVO NOVO-NORDISK A/S-SPONS ADR 13.67 218.01B
MRK MERCK & CO. INC. 10.37 200.44B
PFE PFIZER INC 7.36 134.29B
SNY SANOFI-ADR 11.03 116.44B
BMY BRISTOL-MYERS SQUIBB CO 6.74 92.30B
GSK GSK PLC-SPON ADR 8.49 75.93B
ZTS ZOETIS INC 25.14 67.37B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.09 44.96B

About CGTX

Company Profile

CGTX logo image Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.

Company Info

COGNITION THERAPEUTICS INC

Suite 261, 2403 Sidney Street

Pittsburgh PENNSYLVANIA US

Employees: 27

CGTX Company Website

CGTX Investor Relations

Phone: 14127701621

COGNITION THERAPEUTICS INC / CGTX FAQ

What is the stock price of COGNITION THERAPEUTICS INC today?

The current stock price of CGTX is 0.7054 USD. The price increased by 5.69% in the last trading session.


What is the ticker symbol for COGNITION THERAPEUTICS INC stock?

The exchange symbol of COGNITION THERAPEUTICS INC is CGTX and it is listed on the Nasdaq exchange.


On which exchange is CGTX stock listed?

CGTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for COGNITION THERAPEUTICS INC stock?

10 analysts have analysed CGTX and the average price target is 3.32 USD. This implies a price increase of 369.95% is expected in the next year compared to the current price of 0.7054. Check the COGNITION THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is COGNITION THERAPEUTICS INC worth?

COGNITION THERAPEUTICS INC (CGTX) has a market capitalization of 43.73M USD. This makes CGTX a Nano Cap stock.


How many employees does COGNITION THERAPEUTICS INC have?

COGNITION THERAPEUTICS INC (CGTX) currently has 27 employees.


What are the support and resistance levels for COGNITION THERAPEUTICS INC (CGTX) stock?

COGNITION THERAPEUTICS INC (CGTX) has a support level at 0.58 and a resistance level at 0.85. Check the full technical report for a detailed analysis of CGTX support and resistance levels.


Should I buy COGNITION THERAPEUTICS INC (CGTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does COGNITION THERAPEUTICS INC (CGTX) stock pay dividends?

CGTX does not pay a dividend.


When does COGNITION THERAPEUTICS INC (CGTX) report earnings?

COGNITION THERAPEUTICS INC (CGTX) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of COGNITION THERAPEUTICS INC (CGTX)?

COGNITION THERAPEUTICS INC (CGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.74).


What is the Short Interest ratio of COGNITION THERAPEUTICS INC (CGTX) stock?

The outstanding short interest for COGNITION THERAPEUTICS INC (CGTX) is 12.06% of its float. Check the ownership tab for more information on the CGTX short interest.


CGTX Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CGTX. When comparing the yearly performance of all stocks, CGTX is one of the better performing stocks in the market, outperforming 81.9% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CGTX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CGTX. The financial health of CGTX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGTX Financial Highlights

Over the last trailing twelve months CGTX reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 19.57% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -141.7%
ROE -271.39%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%48.15%
Sales Q2Q%N/A
EPS 1Y (TTM)19.57%
Revenue 1Y (TTM)N/A

CGTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to CGTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners18.77%
Ins Owners0.59%
Short Float %12.06%
Short Ratio0.84
Analysts
Analysts82
Price Target3.32 (370.65%)
EPS Next Y51.93%
Revenue Next YearN/A